GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
GUIDED THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.16−0.03 (-15.79%)
Close on Oct 19, 2026
- Market cap
- $15.45M
- P/E (TTM)
- –
- Dividend yield
- –
Guided Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Electromedical & Electrotherapeutic Apparatus companies for comparison
Valuation
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Market Cap | $15.45M | $229.23M |
| Enterprise Value | $15.45M | $194.73M |
| PS Ratio | 23.76 | 3.14 |
Enterprise value
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 23.76 | 2.93 |
Income (trailing twelve months)
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Revenue | $650.00K | $102.39M |
| Gross Profit | $493.00K | $60.36M |
| Operating Income | -$1.98M | -$4.31M |
| Pretax Income | -$3.07M | -$2.26M |
| Net Income | -$3.07M | -$6.57M |
| EBITDA | -$1.98M | -$1.98M |
| EPS (Diluted) | -$0.04 | -$0.07 |
Margins
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 75.8% | 55.1% |
| Operating Margin | -303.8% | -6.04% |
| Pretax Margin | -471.5% | -4.11% |
| Profit Margin | -471.5% | -10.5% |
| EBITDA Margin | -303.8% | -2.67% |
Returns
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -287.1% | -13.3% |
Growth
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 450.8% | 8.85% |
| Revenue Growth (3Y CAGR) | 289.3% | 7.08% |
| Revenue Growth (5Y CAGR) | 49.7% | 11.8% |
Balance sheet
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $12.00K | $37.33M |
| Total Debt | $11.00K | $72.66M |
| Net Cash (Debt) | $1.00K | $3.92M |
| Net Cash Per Share | $0.00 | $0.28 |
| Equity (Book Value) | -$5.76M | $57.36M |
| Book Value Per Share | -$0.06 | $2.81 |
| Tangible Book Value | -$5.76M | $10.71M |
| Working Capital | -$5.64M | $54.64M |
Financial position
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.09 | 2.50 |
| Quick Ratio | 0.00 | 1.54 |
| Interest Coverage | -3.29 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$1.50M | -$653.46K |
Efficiency
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.61 | 0.59 |
| Inventory Turnover | 0.29 | 2.21 |
| Revenue Per Employee | $216.67K | $322.75K |
| Profits Per Employee | -$1.02M | -$52.11K |
| Employee Count | 3 | 197 |
Dividends and yields
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -19.8% | -6.92% |
Shares
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 96,537,300 | 44,856,700 |
| Shares Change (YoY) | 32.3% | 3.35% |
| Shares Change (QoQ) | 0.03% | 0.27% |
| Float | 58,922,100 | 36,934,400 |
| Shares Held by Insiders | 39.0% | 10.6% |
Taxes
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $1.52M |
Scores
| Measure | Guided Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -195.14 | 1.95 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Guided Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.